Gunderson Dettmer represented client Mithril Capital as it co-led the $50M Series A financing of Adagio Therapeutics, a company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses.

In the announcement of the transaction CEO of Adagio Tillman Gerngross said, “The repeated spillover of coronaviruses into the human population is now well documented and requires a more comprehensive strategy, particularly when you take into account the emerging doubts about the robustness and durability of the immune response in SARS-CoV-2 patients.”

The Gunderson deal team was led by Nevin Fox and included Andrew Weymouth.